Trials / Completed
CompletedNCT04261413
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
A Multicenter, Open Label, Two-step, Phase Ia/Ib Study of Tumor Targeted Prodrug RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors. The research is planned as a two-step study (Phase Ia and phase Ib) and accelerated titration design (ATD) is used.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RS-0139 | RS-0139 will be administered for the indication of solid tumors. |
Timeline
- Start date
- 2021-12-13
- Primary completion
- 2026-03-04
- Completion
- 2026-03-04
- First posted
- 2020-02-07
- Last updated
- 2026-03-11
Locations
2 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT04261413. Inclusion in this directory is not an endorsement.